Zai Lab is a holding company. Through its subsidiaries, Co. is a commercial-stage biopharmaceutical company focusing on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of unmet medical need in the China and global markets, including in the fields of oncology, infectious and autoimmune diseases. Co.'s products are: Niraparib, a selective oral, small molecule PARP 1/2 inhibitor with the potential to be a drug for treatment across multiple solid tumor types in China; and Optune, a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die. The ZLAB average annual return since 2017 is shown above.
The Average Annual Return on the ZLAB average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ZLAB average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ZLAB average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|